Ching-Lung Cheung1, Chor-Wing Sing2, Wallis C Y Lau2,3, Gloria H Y Li4, Gregory Y H Lip5,6, Kathryn C B Tan7, Bernard M Y Cheung7, Esther W Y Chan2, Ian C K Wong2,3. 1. Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China. lung1212@hku.hk. 2. Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China. 3. Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK. 4. Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong, China. 5. Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. 6. Liverpool Health Partners, Liverpool, UK. 7. Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Abstract
BACKGROUND: Diabetes mellitus is a common comorbidity of atrial fibrillation (AF), which can complicate the management of AF. The pharmacology of oral anticoagulants (OACs) have been implicated in pathogenesis of diabetes, but the relationship between different OACs and risk of diabetes remains unexamined. This study aimed to evaluate the risk of diabetes with use of different OACs in AF patients. METHODS: Population-based retrospective cohort study using an electronic healthcare database managed by the Hong Kong Hospital Authority. Patients newly diagnosed with AF from 2014 through 2018 and prescribed OACs were included and followed till December 31, 2019. Inverse probability of treatment weighting based on the propensity score (PS) is used to address potential bias due to nonrandomized allocation of treatment. The risks ofdiabetes were compared between different new OAC users using propensity score-weighted cumulative incidence differences (CID). RESULTS: There were 13,688 new users of OACs (warfarin: n = 3454; apixaban: n = 3335; dabigatran: n = 4210; rivaroxaban: n = 2689). The mean age was 75.0 (SD, 11.2), and 6,550 (47.9%) were women. After a median follow-up of 0.93 years (interquartile range, 0.21-1.92 years), 698 incident diabetes cases were observed. In Cox-regression analysis, dabigatran use was significantly associated with reduced risk of diabetes when compared with warfarin use [HR 0.69 (95% CI 0.56-0.86; P < 0.001)], with statistically insignificant associations observed for use of apixaban and rivaroxaban. The corresponding adjusted CIDs at 2 years after treatment with apixaban, dabigatran, and rivaroxaban users when compared with warfarin were - 2.06% (95% CI - 4.08 to 0.16%); - 3.06% (95% CI - 4.79 to - 1.15%); and - 1.8% (- 3.62 to 0.23%). In head-to-head comparisons between women DOAC users, dabigatran was also associated with a lower risk of diabetes when compared with apixaban and rivaroxaban. CONCLUSIONS: Among adults with AF receiving OACs, the use of dabigatran had the lowest risk of diabetes when compared with warfarin use.
BACKGROUND:Diabetes mellitus is a common comorbidity of atrial fibrillation (AF), which can complicate the management of AF. The pharmacology of oral anticoagulants (OACs) have been implicated in pathogenesis of diabetes, but the relationship between different OACs and risk of diabetes remains unexamined. This study aimed to evaluate the risk of diabetes with use of different OACs in AFpatients. METHODS: Population-based retrospective cohort study using an electronic healthcare database managed by the Hong Kong Hospital Authority. Patients newly diagnosed with AF from 2014 through 2018 and prescribed OACs were included and followed till December 31, 2019. Inverse probability of treatment weighting based on the propensity score (PS) is used to address potential bias due to nonrandomized allocation of treatment. The risks ofdiabetes were compared between different new OAC users using propensity score-weighted cumulative incidence differences (CID). RESULTS: There were 13,688 new users of OACs (warfarin: n = 3454; apixaban: n = 3335; dabigatran: n = 4210; rivaroxaban: n = 2689). The mean age was 75.0 (SD, 11.2), and 6,550 (47.9%) were women. After a median follow-up of 0.93 years (interquartile range, 0.21-1.92 years), 698 incident diabetes cases were observed. In Cox-regression analysis, dabigatran use was significantly associated with reduced risk of diabetes when compared with warfarin use [HR 0.69 (95% CI 0.56-0.86; P < 0.001)], with statistically insignificant associations observed for use of apixaban and rivaroxaban. The corresponding adjusted CIDs at 2 years after treatment with apixaban, dabigatran, and rivaroxaban users when compared with warfarin were - 2.06% (95% CI - 4.08 to 0.16%); - 3.06% (95% CI - 4.79 to - 1.15%); and - 1.8% (- 3.62 to 0.23%). In head-to-head comparisons between womenDOAC users, dabigatran was also associated with a lower risk of diabetes when compared with apixaban and rivaroxaban. CONCLUSIONS: Among adults with AF receiving OACs, the use of dabigatran had the lowest risk of diabetes when compared with warfarin use.
Authors: Daniel F McCaffrey; Beth Ann Griffin; Daniel Almirall; Mary Ellen Slaughter; Rajeev Ramchand; Lane F Burgette Journal: Stat Med Date: 2013-03-18 Impact factor: 2.373
Authors: Sharon W Y Law; Wallis C Y Lau; Ian C K Wong; Gregory Y H Lip; Michael T Mok; Chung-Wah Siu; Esther W Chan Journal: J Am Coll Cardiol Date: 2018-07-09 Impact factor: 24.094
Authors: Chor-Wing Sing; Angel Ys Wong; Douglas P Kiel; Elaine Yn Cheung; Joanne Ky Lam; Tommy T Cheung; Esther W Chan; Annie Wc Kung; Ian Ck Wong; Ching-Lung Cheung Journal: J Bone Miner Res Date: 2018-05-09 Impact factor: 6.741
Authors: Joline W J Beulens; Daphne L van der A; Diederick E Grobbee; Ivonne Sluijs; Annemieke M W Spijkerman; Yvonne T van der Schouw Journal: Diabetes Care Date: 2010-04-27 Impact factor: 17.152
Authors: Chor-Wing Sing; Casey Tze Lam Tang; Celine Sze Ling Chui; Min Fan; Francisco Tsz Tsun Lai; Xue Li; Eric Yuk Fai Wan; Carlos King Ho Wong; Esther Wai Yin Chan; Ivan Fan Ngai Hung; Anskar Yu-Hung Leung; Ching-Lung Cheung; Ian Chi Kei Wong Journal: Am J Hematol Date: 2022-02-09 Impact factor: 10.047